These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 11040033)

  • 1. Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5.
    Shapiro DA; Kristiansen K; Kroeze WK; Roth BL
    Mol Pharmacol; 2000 Nov; 58(5):877-86. PubMed ID: 11040033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation.
    Wang CD; Gallaher TK; Shih JC
    Mol Pharmacol; 1993 Jun; 43(6):931-40. PubMed ID: 8316224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves.
    Kurrasch-Orbaugh DM; Watts VJ; Barker EL; Nichols DE
    J Pharmacol Exp Ther; 2003 Jan; 304(1):229-37. PubMed ID: 12490596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
    Blair JB; Kurrasch-Orbaugh D; Marona-Lewicka D; Cumbay MG; Watts VJ; Barker EL; Nichols DE
    J Med Chem; 2000 Nov; 43(24):4701-10. PubMed ID: 11101361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism.
    Kristiansen K; Kroeze WK; Willins DL; Gelber EI; Savage JE; Glennon RA; Roth BL
    J Pharmacol Exp Ther; 2000 Jun; 293(3):735-46. PubMed ID: 10869371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines.
    Johnson MP; Loncharich RJ; Baez M; Nelson DL
    Mol Pharmacol; 1994 Feb; 45(2):277-86. PubMed ID: 8114677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of 5-HT(2) receptors in the tryptamine-induced 5-HT syndrome in rats.
    Van Oekelen D; Megens A; Meert T; Luyten WH; Leysen JE
    Behav Pharmacol; 2002 Jul; 13(4):313-8. PubMed ID: 12218512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors.
    Choudhary MS; Craigo S; Roth BL
    Mol Pharmacol; 1993 May; 43(5):755-61. PubMed ID: 8388989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors.
    Roth BL; Shoham M; Choudhary MS; Khan N
    Mol Pharmacol; 1997 Aug; 52(2):259-66. PubMed ID: 9271348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of transmembrane IV and V serines indicate that all tryptamines do not bind to the rat 5-HT2A receptor in the same manner.
    Johnson MP; Wainscott DB; Lucaites VL; Baez M; Nelson DL
    Brain Res Mol Brain Res; 1997 Oct; 49(1-2):1-6. PubMed ID: 9387857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities.
    Sleight AJ; Stam NJ; Mutel V; Vanderheyden PM
    Biochem Pharmacol; 1996 Jan; 51(1):71-6. PubMed ID: 8534270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model.
    Roth BL; Choudhary MS; Khan N; Uluer AZ
    J Pharmacol Exp Ther; 1997 Feb; 280(2):576-83. PubMed ID: 9023266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus.
    Almaula N; Ebersole BJ; Ballesteros JA; Weinstein H; Sealfon SC
    Mol Pharmacol; 1996 Jul; 50(1):34-42. PubMed ID: 8700116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-directed mutagenesis of the 5-HT1B receptor increases the affinity of 5-HT for the agonist low-affinity conformation and reduces the intrinsic activity of 5-HT.
    Grånäs C; Nordquist J; Mohell N; Larhammar D
    Eur J Pharmacol; 2001 Jun; 421(2):69-76. PubMed ID: 11399261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6.
    Shapiro DA; Kristiansen K; Weiner DM; Kroeze WK; Roth BL
    J Biol Chem; 2002 Mar; 277(13):11441-9. PubMed ID: 11801601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.
    Fitzgerald LW; Conklin DS; Krause CM; Marshall AP; Patterson JP; Tran DP; Iyer G; Kostich WA; Largent BL; Hartig PR
    J Neurochem; 1999 May; 72(5):2127-34. PubMed ID: 10217294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characteristics and regulation of 5-HT receptor-stimulated phosphoinositide hydrolysis in the rat spinal cord.
    Toscano E; Romero G; Oset C; Del Río J
    Gen Pharmacol; 1999 Mar; 32(3):351-8. PubMed ID: 10211591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of the ligand binding site of the human 5-HT(4) receptor by site-directed mutagenesis and molecular modeling.
    Mialet J; Dahmoune Y; Lezoualc'h F; Berque-Bestel I; Eftekhari P; Hoebeke J; Sicsic S; Langlois M; Fischmeister R
    Br J Pharmacol; 2000 Jun; 130(3):527-38. PubMed ID: 10821780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor.
    Boess FG; Monsma FJ; Meyer V; Zwingelstein C; Sleight AJ
    Mol Pharmacol; 1997 Sep; 52(3):515-23. PubMed ID: 9284367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of amino acid residues important for sarpogrelate binding to the human 5-hydroxytryptamine2A serotonin receptor.
    Muntasir HA; Rashid M; Komiyama T; Kawakami J; Nagatomo T
    J Pharmacol Sci; 2006 Sep; 102(1):55-63. PubMed ID: 16974069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.